SCHEDULE: Redmile Group Updates Atara Biotherapeutics Stake

Redmile Group reports a change in beneficial ownership percentage of Atara Biotherapeutics due to shifts in the issuer's outstanding share count.

Summary

• Redmile Group, LLC and associated entities reported an increase in their beneficial ownership percentage of Atara Biotherapeutics, Inc. common stock to 9.9%.
• The change in percentage is attributed solely to an increase in the total number of outstanding shares of the issuer's common stock, rather than any new purchase or sale of securities.
• The reporting persons hold 950,994 shares in aggregate, which includes 441,701 shares of common stock and 509,293 shares issuable upon the exercise of pre-funded warrants.
• The warrant exercise is subject to a 9.99% beneficial ownership limitation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting a change in ownership percentage due to share dilution or issuance, rather than a change in investment sentiment.

Positives

• The filing confirms that the reporting entity has not sold any shares, maintaining their long-term investment position in the company.

Negatives

• The increase in beneficial ownership percentage is a technical result of changes in the issuer's capital structure rather than an active accumulation of shares.

Risks

• The investment is subject to a 9.99% beneficial ownership limitation, which restricts the immediate conversion of warrants into common stock.
• The value of the holding is tied to the performance of Atara Biotherapeutics, which is subject to the inherent risks of the biotechnology sector.

Future Outlook

The filing does not provide forward-looking guidance regarding the company's operations, focusing instead on the reporting of ownership interests.

Industry Context

StockSavvy.ai notes that institutional investors in the biotech space often utilize pre-funded warrants to manage ownership stakes while navigating regulatory thresholds like the 9.99% beneficial ownership limit.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for institutional investors holding significant stakes in small-cap biotechnology firms.

Stakeholder Impact

• Shareholders should note the continued significant interest from Redmile Group, which remains a major institutional holder.

Next Steps

• The reporting persons will continue to monitor their ownership levels relative to the 9.99% beneficial ownership limitation.

Key Dates

Keywords

Atara Biotherapeutics, Redmile Group, Schedule 13D, Beneficial Ownership, Biotech, Warrants